Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DPX-BRAF + cyclophosphamide
- Development stage
- Preclinical
- Lead developer
- BioVaxys Technology Corporation
- Modality
- Small Molecules, Vaccines & Immunotherapeutics
- Administration
- Subcutaneous, Oral, Intravenous
01
Overview
DPX-BRAF + cyclophosphamide is an investigational cancer immunotherapy regimen consisting of DPX-BRAF, a depot-formulated therapeutic vaccine targeting BRAF-derived peptides, administered together with low-dose cyclophosphamide as an immune-modulating chemotherapeutic. DPX-BRAF is based on the DPX (DepoVax) platform, which presents tumor-associated antigens in a lipid-in-oil formulation designed to induce durable, antigen-specific CD4+ and CD8+ T-cell responses against BRAF-mutant tumor cells. Low-dose cyclophosphamide is used primarily for its immunomodulatory effect, particularly depletion or functional inhibition of regulatory T cells, thereby enhancing vaccine-induced anti-tumor T-cell activity. The combination is being developed for BRAF-mutant solid tumors, leveraging vaccine-induced T-cell cytotoxicity together with cyclophosphamide-mediated modulation of the tumor immune microenvironment.[7]
- Other names
- DPX BRAF/CPABPX-BRAF/CPADPX-BRAF + CPADPX-BRAF cancer vaccine + low-dose cyclophosphamide
02
Targets
DNABRAF-derived peptide-MHC complex
Beyond the preview
Go deeper on DPX-BRAF + cyclophosphamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DPX-BRAF + cyclophosphamide.